Eledon reports inducement grants under nasdaq listing rule 5635(c)(4)

Irvine, calif., june 10, 2022 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that the company's compensation committee granted new employees inducement stock options to purchase an aggregate of 180,000 common shares, at a per share exercise price of $3.06, the closing price of eledon's common stock on june 6, 2022. the stock options were granted as inducements material to the new employees entering employment with eledon in accordance with nasdaq listing rule 5635(c)(4).
ELDN Ratings Summary
ELDN Quant Ranking